MedTrace Logo

OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)

NCT02719639 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7443

Last updated 2019-01-09

Study results available
· View outcomes & findings →

Summary

Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need treatment with two long-acting bronchodilators, is not available. This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto Respimat according to the approved Summary of Product Characteristics (SmPC).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Austria
  • Czechia
  • Hungary
  • Israel
  • Romania
  • Russia
  • Slovakia
  • Slovenia
  • Switzerland

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02719639 on ClinicalTrials.gov